Literature DB >> 22315428

Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Martin Lundblad1, Mickael Decressac, Bengt Mattsson, Anders Björklund.   

Abstract

We used in vivo amperometry to monitor changes in synaptic dopamine (DA) release in the striatum induced by overexpression of human wild-type α-synuclein in nigral DA neurons, induced by injection of an adeno-associated virus type 6 (AAV6)-α-synuclein vector unilaterally into the substantia nigra in adult rats. Impairments in DA release evolved in parallel with the development of degenerative changes in the nigrostriatal axons and terminals. The earliest change, seen 10 d after vector injection, was a marked, ≈50%, reduction in DA reuptake, consistent with an early dysfunction of the DA transporter that developed before any overt signs of axonal damage. At 3 wk, when the first signs of axonal damage were observed, the amount of DA released after a KCl pulse was reduced by 70-80%, and peak DA concentration was delayed, indicating an impaired release mechanism. At later time points, 8-16 wk, overall striatal innervation density was reduced by 60-80% and accompanied by abundant signs of axonal damage in the form of α-synuclein aggregates, axonal swellings, and dystrophic axonal profiles. At this stage DA release and reuptake were profoundly reduced, by 80-90%. The early changes in synaptic DA release induced by overexpression of human α-synuclein support the idea that early predegenerative changes in the handling of DA may initiate, and drive, a progressive degenerative process that hits the axons and terminals first. Synaptic dysfunction and axonopathy would thus be the hallmark of presymptomatic and early-stage Parkinson disease, followed by neuronal degeneration and cell loss, characteristic of more advanced stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315428      PMCID: PMC3295273          DOI: 10.1073/pnas.1200575109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Striatal dopamine deficiency in Parkinson's disease: role of aging.

Authors:  D Scherman; C Desnos; F Darchen; P Pollak; F Javoy-Agid; Y Agid
Journal:  Ann Neurol       Date:  1989-10       Impact factor: 10.422

2.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

3.  Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein.

Authors:  Deborah E Cabin; Kazuhiro Shimazu; Diane Murphy; Nelson B Cole; Wolfram Gottschalk; Kellie L McIlwain; Bonnie Orrison; Amy Chen; Christopher E Ellis; Richard Paylor; Bai Lu; Robert L Nussbaum
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

4.  Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Authors:  Deniz Kirik; Carl Rosenblad; Corinna Burger; Cecilia Lundberg; Teit E Johansen; Nicholas Muzyczka; Ronald J Mandel; Anders Björklund
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

5.  Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.

Authors:  Jin Xu; Shyan-Yuan Kao; Frank J S Lee; Weihong Song; Lee-Way Jin; Bruce A Yankner
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

6.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

7.  Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines.

Authors:  Melisa J Baptista; Casey O'Farrell; Sneha Daya; Rili Ahmad; David W Miller; John Hardy; Matthew J Farrer; Mark R Cookson
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

8.  Ageing and Parkinson's disease: substantia nigra regional selectivity.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1991-10       Impact factor: 13.501

Review 9.  alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.

Authors:  Anita Sidhu; Christophe Wersinger; Philippe Vernier
Journal:  FEBS Lett       Date:  2004-05-07       Impact factor: 4.124

Review 10.  Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?

Authors:  Anita Sidhu; Christophe Wersinger; Philippe Vernier
Journal:  FASEB J       Date:  2004-04       Impact factor: 5.191

View more
  123 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

Review 2.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

3.  Imaging Mass Spectrometric Analysis of Neurotransmitters: A Review.

Authors:  Gustavo A Romero-Perez; Shiro Takei; Ikuko Yao
Journal:  Mass Spectrom (Tokyo)       Date:  2015-03-07

4.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 5.  The physiological role of α-synuclein and its relationship to Parkinson's Disease.

Authors:  David Sulzer; Robert H Edwards
Journal:  J Neurochem       Date:  2019-07-28       Impact factor: 5.372

Review 6.  A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.

Authors:  Giulia Ambrosi; Silvia Cerri; Fabio Blandini
Journal:  J Neural Transm (Vienna)       Date:  2014-01-01       Impact factor: 3.575

7.  The clathrin-dependent localization of dopamine transporter to surface membranes is affected by α-synuclein.

Authors:  Haya Kisos; Tziona Ben-Gedalya; Ronit Sharon
Journal:  J Mol Neurosci       Date:  2013-09-19       Impact factor: 3.444

Review 8.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

9.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

10.  Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Authors:  Christina E Khodr; Amanda Becerra; Ye Han; Martha C Bohn
Journal:  Brain Res       Date:  2014-01-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.